Clinical Evaluation of [68Ga]Ga-NOTA-RF PET Imaging Targeting RFVT3 in Patients With Pituitary Tumors

Exclusion Criteria

• •1. Pregnant or planning to become pregnant, or breastfeeding women.
• •2. Known history of severe allergic or anaphylactoid reactions to any component of the investigational tracer (riboflavin derivatives, NOTA chelator, or formulation excipients).
• •3. Presence of severe or uncontrolled medical conditions (e.g., decompensated heart failure, active infection, myocardial infarction or stroke within the past 4 weeks) that, in the opinion of the investigator, make the participant unsuitable for PET imaging.
• •4. Concomitant severe systemic diseases such as cardiac, pulmonary, hepatic, or renal failure.
• •5. Pituitary adenoma patients who underwent surgery less than 4 weeks prior to enrollment or completed radiotherapy to the sellar region within the past 3 months.
• •6. Participation in another interventional clinical trial within the past 4 weeks, or cumulative radiation exposure from prior research procedures within the past 12 months that may exceed the ethical safety limit.
• •7. Severe claustrophobia unrelieved by sedation, or any other condition that would prevent completion of the PET scan.
• •8. Poor compliance or any factor judged by the investigator to affect the participant's safety or the quality of study data.
• •9. Any other condition that, in the judgment of the investigator, makes the participant unsuitable for study participation.